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The Smoothened receptor (SMO) belongs to the Class Frizzled of the G protein-coupled
receptor (GPCR) superfamily, constituting a key component of the Hedgehog signalling
pathway. Here we report the crystal structure of the multi-domain human SMO, bound and
stabilized by a designed tool ligand TC114, using an X-ray free-electron laser source at 2.9Å.
The structure reveals a precise arrangement of three distinct domains: a seven-transmembrane
helices domain (TMD), a hinge domain (HD) and an intact extracellular cysteine-rich domain
(CRD). This architecture enables allosteric interactions between the domains that are
important for ligand recognition and receptor activation. By combining the structural data,
molecular dynamics simulation, and hydrogen-deuterium-exchange analysis, we demonstrate
that transmembrane helix VI, extracellular loop 3 and the HD play a central role in
transmitting the signal employing a unique GPCR activation mechanism, distinct from other
multi-domain GPCRs.
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T
he Hedgehog (Hh) signalling pathway plays a key role in
embryonic development and the regulation of adult stem
cells. Uncontrolled activation of the Hh pathway results in
numerous cancers in the brain, muscle and skin, and has drawn
extensive attention from the drug discovery perspective1.
The smoothened receptor (SMO)2,3, a Class Frizzled seven-
transmembrane helices (7TM) G protein-coupled receptor
(GPCR), is a key component in this signalling pathway4. The
activity of SMO is suppressed by the PTCH receptor1, a 12TM
protein. This suppression is disabled when Hh binds to PTCH,
leading to phosphorylation of SMO’s cytoplasmic region5, which
induces the translocation of GLI transcription factors into the
nucleus to activate target genes6. However, the interaction
between PTCH and SMO, and the release of PTCH suppression
by Hh binding are not clearly understood. Previous biochemical
and functional characterization studies have indicated that SMO
contains at least two non-overlapping ligand binding pockets7.
One of them is located inside the transmembrane domain (TMD)
resembling the canonical ligand binding pocket in Class A
GPCRs, targeted by numerous small molecules, including
inhibitors and activators3,8,9. Another ligand-binding site is
situated on the surface of the extracellular cysteine-rich domain
(CRD), targeted by 20(S)-hydroxycholesterol (OHC) and other
cholesterol analogues10–12. SMO constructs without the CRD
show increased constitutive activity, suggesting an auto-inhibitory
effect of the CRD on the receptor’s activation6,13. Yet, the
mechanism of how oxysterols activate Hh signalling and release
CRD suppression remains unclear. Here, we present the crystal
structure of the multi-domain human SMO in complex with a
specially designed TMD ligand, shedding light on interactions
between the CRD and TMD. Combining the structures with
biophysical characterization and computer modelling results,
we propose a mechanistic model of SMO activation.
Results
Rational design of a novel ligand for structural studies.
CRD truncated SMO (DCRD–SMO) has been previously
co-crystallized with several small molecules, including both
antagonists and agonists3,8,9. These ligands and others failed to
yield crystals of the multi-domain SMO containing an intact CRD
without stabilizing mutations. Analysis of previous DCRD–SMO
structures3,8,9 suggests that crystallization of a multi-domain
SMO might require stabilization of some specific flexible parts of
the structure. For example, we found that K395, located on top of
the b-hairpin on extracellular loop 2, can engage in interactions
with either adjacent residues or ligands3, and thus probably adopt
a dynamic conformational state (Fig. 1a). Thus, we hypothesized
that further stabilization of this region by establishing a defined
and stronger interaction might reduce the conformational
heterogeneity.
For this purpose, we screened several commercial ligands using
the CPM thermal shift assay14 and chose LY2940680, which had
the highest Tm value, as our starting point for design of new
ligands (Supplementary Fig. 1a). A series of compounds were
then synthesized with modifications on the 2- and 4-positions of
the benzoyl moiety of LY2940680 (Fig. 1b). Structure-activity
relationship (SAR) analysis demonstrated the significance of these
substitutions. First, removal of the 2-trifluoromethyl group
lowered stability of the multi-domain SMO (TC101-104),
indicating that the 2-trifluoromethyl group is essential and
should be preserved (Fig. 1c). Next, several substituents were
introduced by replacing the 4-fluorine atom to generate a
stronger interaction between the ligands and adjacent residues.
One of these ligands, TC114, with the 4-nitro group substitution,
was predicted to form an electrostatic interaction with the
protonated e-amine of K395. Computer docking analysis
suggested that a distance of 3.4 Å between the amine and
nitro groups would be right within the electrostatic or
enhanced hydrogen-bond interaction distance. Consistent with
the prediction, a CPM assay of LY2940680 analogues showed
that TC114 confers a much stronger stabilizing effect on the
multi-domain SMO (Tm¼ 76 C) compared to LY2940680
(Tm¼ 68 C) and other tested analogues (Fig. 1c; Supplementary
Fig. 1a). Functional characterization of TC114 in a cell-based
SMO activation assay confirmed the antagonist activity of TC114
on wild type (WT) SMO and reduced inhibition activity on the
drug-resistant mutant (D473H)15 (Supplementary Fig. 2a).
Analysis of our multi-domain SMO structures indicated that
the nitro group introduced in the TC114 ligand does interact
strongly with K395 in SMO as designed, and enhance the p–p
stacking between the benzoyl group and F484 on helix VI
(Fig. 1d). Therefore, we conclude that TC114 stabilizes the
multi-domain SMO by keeping helix VI in a stable conformation
that in turn enhances the hydrophobic interaction between
the extended ECL3 and the CRD hydrophobic groove. Thus,
the designed ligand TC114 achieved the desired goal, acting as a
super stabilizing agent in the thermal stability assay and enabling
the multi-domain SMO co-crystallization study.
Overall architecture of the multi-domain human SMO. To
facilitate crystallization, human SMO was engineered by fusion of
a Flavodoxin (FLA)16 protein between helices V and VI, replacing
part of intracellular loop 3 (ICL3) between P434 and S443. The N
terminus 1–52 and C terminus 559–787 were truncated and a
single-mutation E194M was made in the hinge domain (HD),
which slightly increased the protein yield without affecting its
stability compared to the construct without this mutation
(Supplementary Figs 1b and 3). We also assessed the effect of
this single point mutation on the receptor signalling activity, and
noticed that E194M mutant showed some increased activity
compared to the WT (Supplementary Fig. 2b). The resulting
SMO–FLA construct was co-expressed with vismodegib17, and
then purified and crystallized in complex with TC114 using the
lipidic cubic phase method18. We determined the structure using
room temperature data collected at an X-ray free-electron laser
(XFEL) source at 2.9 Å resolution (Supplementary Fig. 4). At
the same time, we also solved the structure with data from 12
cryo-cooled crystals collected at a synchrotron source at 3.0 Å
resolution (Supplementary Fig. 4). Since the room temperature
XFEL crystal structure potentially represents a closer-to-native
receptor conformation and at a slightly higher resolution than the
synchrotron structure obtained at cryo-cooled conditions, we
describe the XFEL SMO structure below, unless noted otherwise.
The overall SMO structure (Fig. 2a; Supplementary Fig. 4)
shares a canonical GPCR 7TM bundle fold with an amphipathic
helix VIII running parallel to the membrane plane. The CRD is
positioned straight up on top of the TMD and is supported by
extracellular loop 3 (ECL3) on one side and by a linker loop
(residues 181–190) on the other. The CRD and TMD are
connected by the HD (residues 191–220). Furthermore, on the
extracellular side of the structure (Fig. 2b), helix VI is extended
beyond the membrane surface by four a-helical turns, and the top
part of helix VI is tilted at a non-proline kink towards the CRD,
protruding into its hydrophobic groove and bridging a key
connection between the CRD and TMD. A hydrophobic pocket is
formed by the CRD (residues V107, L108, L112), HD (residue
V210) and ECL3 (residues V494, I496) (Fig. 2c). This pocket was
previously reported to constitute an oxysterol binding site7,19.
Unique multi-domain interaction. As this manuscript was
under preparation, Byrne et al. published two multi-domain SMO
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structures20 and, therefore, we compared our XFEL structure
with their vismodegib-bound and cholesterol-bound structures
(Fig. 3a). Overall, the three structures are very similar with the
TMD parts overlapping almost perfectly. The largest difference is
in the mutual orientations of the CRD, ECL3 and HD. The CRDs
in these three structures show substantial tilts between each other
with respect to the aligned TMDs. In the vismodegib-bound
structure, the CRD tilts by B3 towards the straight up
conformation perpendicular to the membrane plane20. In the
cholesterol-bound structure, however, the CRD tilts by B7 in
the opposite direction along with an outward shift of both ECL3
and the upper part of helix VI compared to our XFEL structure
(Fig. 3b). ECL3 in the cholesterol-bound structure makes an extra
a-helical turn and shifts outward by as much as 7Å compared to
our XFEL structure (Fig. 3b), emphasizing the flexibility of this
part of the structure and potential role of ECL3 in regulation of
sterol binding to the CRD. Interestingly, in our XFEL structure,
a glycan modification is observed on N493, which is also present
in the vismodegib-bound and cholesterol-bound structures,
although faced to a slightly different solvent side. In the
vismodegib-bound structure, the glycan partially occupies the
cholesterol binding site precluding cholesterol or oxysterol
binding to the vismodegib-bound structure, whereas in our
XFEL structure the side chain of I496 from ECL3 extends into the
cholesterol binding site, also precluding cholesterol or oxysterol
binding to the CRD (Fig. 3b). This different glycan orientation is
related to the aforementioned different ECL3 conformations
between our XFEL structure and the cholesterol-bound structure.
In addition, the HD in the cholesterol-bound structure moves
towards the TM helices byB2Å compared to the TC114-bound
structure (Fig. 3c). Comparison of our XFEL multi-domain SMO
structure with the five previously reported DCRD–SMO
structures3,8,9, and with the vismodegib-bound multi-domain
SMO structure20 showed that the TMD bundle and the TMD
ligand binding pockets are highly consistent (Fig. 3d). The TMDs
of these structures including loop regions are all very similar,
except for different conformations of ECL3 and subtle differences
at the intracellular end of helix V, likely related to different
orientations of fusion partners in the crystal structures.
In the recently published work describing Xenopus laevis SMO
(xSMO) CRD structures, the authors proposed that sterol binding
induces a conformational change in the CRD (from ‘open’
to ‘closed’ conformation) and this conformational change is
sufficient for SMO activation21. We compared SMO CRDs of the
cholesterol-bound and our XFEL multi-domain SMO structures,
with the three xSMO CRD structures in the apo state, bound to
cyclopamine and bound to OHC (Fig. 3e). Binding of CRD
agonists OHC or cyclopamine induces conformational changes in
the CRD that mainly involve the displacement of key residues
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Figure 1 | Design and synthesis of SMO ligand TC114 for crystallographic studies. (a) Close-up view of the LY2940680 binding pocket in DCRD–SMO
structure (PBD ID: 4JKV). (b) Design and evolution of LY2940680 analogues for crystallization study by variation of the substituents on aromatic ring.
(c) The representative Tm values for LY2940680 and its analogues according to the CPM thermal shift assay. (d) Close-up view of TC114 binding pocket.
TC114 (orange carbons) and SMO residues (cyan carbons) involved in ligand binding are shown in stick representation. The receptor is shown in light blue
cartoon representation. Other elements are coloured as follows: oxygen, red; nitrogen, dark blue; sulfur, yellow. Hydrogen bonds are displayed as magenta
dashed lines.
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compared to the apo xSMO CRD structure21. Superposition of
these CRD structures with CRDs of the multi-domain SMO
structures showed that these key residues in both cholesterol-
bound and our XFEL multi-domain SMO structures are in a
conformation that is consistent with the OHC- or cyclopamine-
bound, but not apo, CRD. This may indicate that conformational
changes in the CRD are restricted, when it is placed in the context
of the entire multi-domain SMO structure, where it always adopts
a ‘closed’ conformation regardless of sterol binding. In fact, our
structure demonstrates that in the absence of sterol binding,
ECL3 interacts with the CRD hydrophobic groove to stabilize the
CRD in a ‘closed’ conformation (Fig. 2c). The observation of
limited, if any, conformational changes within the CRD itself on
ligand binding is also supported by a recent publication by
Luchetti et al.12, where authors proposed a model of how
cholesterol activates Hedgehog signalling through binding to
SMO. Therefore, the conserved conformations of CRD itself,
as observed in the multi-domain SMO structures may not be
sufficient for SMO activation. Conformational modularity on the
CRD anchoring region—ECL3, instead, is rather critical. Point
mutations on ECL3, including N493Q and I496R, lead to SMO
constitutive activity, consistent with the self-inhibitory role of
CRD to the receptor basal activity11 (Supplementary Fig. 2b).
To probe the flexibility of SMO ‘hotspots’ in solution,
we performed hydrogen-deuterium exchange (HDX) analysis
using the purified SMO protein with or without ligands. HDX
occurs in solvent accessible parts of the protein, so changes in
conformation on ligand binding that expose or mask protein
regions can be measured by the altered hydrogen-deuterium
exchange rates. Interestingly, we did not observe any changes in
the solvent deuterium uptake kinetics, when comparing the apo
receptor to either the CRD agonist OHC-bound or CRD
antagonist 22-azacholesterol (NHC)-bound receptors. Adding
TMD ligand TC114, however, induced protection to exchange
(slower exchange) at regions mostly on the cytoplasmic side of
the receptor (Supplementary Fig. 5). This analysis demonstrates
that although no TMD rearrangements were observed on the
cytoplasmic side in any SMO crystal structures solved to date, the
possibility that this region is intrinsically dynamic and subject to
conformational changes on signal transduction could not be
ruled out. Similarly, in a 1ms-long molecular dynamics (MD)
simulations with SMO in the presence of cholesterol and
embedded in a lipid environment (Supplementary Fig. 6),
we do not see large degree of movement on the CRD nor TMD
domains, suggesting that these domains are rather constrained
when being activated and the structural stability is important for
its functionality. This MD result is interesting, as we originally
expected higher flexibility on the CRD region; yet it is consistent
with our observation from the HDX analysis, as well as with
the 100-ns MD result reported by Byrne et al.20 Our longer-time
MD simulation showed that cholesterol-bound SMO CRD leans
towards the membrane plane, in agreement with the observation
from our structural comparison between TC114-bound and
cholesterol-bound SMO structures (Fig. 3a). Further investigation
along this line is required to draw more comprehensive
conclusion, particularly regarding the degree of freedom on the
multi-domains.
Comparison of human SMO with other class frizzled receptors.
Superposition of the CRDs between human SMO and mouse
Frizzled-8 (mFzd-8) or human Frizzled-4 (hFzd-4) receptors
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Figure 2 | Overall structure of the multi-domain human SMO. (a) Overall structure of the human SMO in complex with TC114 determined at an XFEL.
TC114 is shown as orange sticks. The CRD, linker, HD and TMD are indicated as orange, marine, green cyan and light blue cartoons, respectively.
The membrane boundary is labelled, as an orange dashed line. N-linked glycans (NAG) are shown in green sticks. (b) Top view of the SMO from the
extracellular side. A hydrophobic pocket is formed by the CRD hydrophobic groove and ECL3 (marine loop). (c) Key residues in the CRD and ECL3 defining
the hydrophobic pocket are shown in cyan and light blue sticks, respectively.
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(Fig. 4a) reveals a highly conserved architecture and highlights a
closely related role of the CRD for ligand recognition. Moreover,
sequence alignment of all human Class Frizzled GPCRs
(SMO and ten Frizzled receptors) indicates the existence of a
hydrophobic groove (site 1) in all CRDs, and a hydrophobic patch
(site 2) on the opposite side of the CRD22,23, which exists only in
Frizzled receptors (Supplementary Fig. 7). In the crystal structure
of mFzd-8 CRD in complex with its native ligand homologue
xWnt8, a palmitoyl group modification on xWnt8 was discovered
bound to the hydrophobic groove (site 1) (Fig. 4b). The key
residues, Q71, F72, P74, L75, I78, M122, Y125, F127 of mFzd-8,
which form this site 1 hydrophobic groove, are highly conserved
within all Class Frizzled receptors including SMO. At the
hydrophobic patch site 2, Norrin, a secreted retinal vascular
growth factor, recognized as an endogenous ligand only for
Fzd-4, uses an extended hydrophobic interface to interact with
Fzd-4’s CRD23 (Fig. 4c). The hydrophobic patch is formed by
residues from hFzd-4 CRD F96, M105, I110, M157 and M159. In
the mFzd-8 CRD-xWnt8 structure, a long finger loop from Wnt
also extends into the same hydrophobic patch interacting with
site 2. This hydrophobic patch (or site 2) is conserved in all 10
Frizzled receptors. Surface hydrophobicity analysis indicates that
while the interface of hFzd-4 and Norrin is very hydrophobic, the
same site is hydrophilic in SMO (Fig. 4c). The absence of a
hydrophobic patch in SMO, however, argues against the existence
of a hydrophobic binding mode in this site, and indicates that site
1 may be the only binding site for endogenous sterols or yet
unidentified sterol-modified protein ligands.
Discussion
The mechanism of how the binding of an agonist to the CRD
triggers a conformational change in the TMD remains obscure.
As noted, binding of cholesterol to the multi-domain SMO
induces an B7 tilt of the CRD, which is associated with three
major conformational changes: the extracellular extension of helix
VI tilts outward byB5, ECL3 forms an extra a-helical turn and
shifts outward by 7Å, and the HD is displaced towards the TMD
by 2Å compared to the TC114-bound structure (Fig. 3a–c). In the
xSMO cyclopamine-bound CRD structure, the E and F rings of
cyclopamine, which acts as an agonist when bound to the CRD,
clash with helix VI of the cholesterol-bound multi-domain SMO
structure, indicating that helix VI and ECL3 should shift outward
even further when cyclopamine is bound to the CRD in a multi-
domain SMO (Fig. 3e). Structure-guided mutagenesis on HD,
V198R and K204A, which disrupted the conformational integrity
of HD, can inhibit 20(S)-OHC induced signalling to these
mutants without affecting Sonic Hedgehog (Shh) induced
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Figure 3 | Unique multi-domain interaction and modularity in the human SMO. (a) Superposition of three multi-domain SMO structures: SMO solved at
XFEL, SMO in complex with cholesterol (PBD ID: 5L7D) and SMO in complex with vismodegib (PBD ID: 5L7I) are shown in light blue, pink and lime green
cartoons, respectively. The cholesterol in the 5L7D structure is shown in marine spheres. (b) Top view of the extracellular side. The glycans from XFEL,
cholesterol-bound and vismodegib-bound structures are shown in light blue, pink and lime green sticks, respectively. I496 from XFEL structure is shown in
red sticks. (c) Hinge domains (HDs) from SMO in complex with TC114 (light blue) and SMO in complex with cholesterol (PBD ID: 5L7D; pink) are
superimposed and shown as cartoons. (d) Close-up view of superimposed structures of the TMD bundle of SMO with different ligands bound. SMO in
complex with TC114 (light blue), SMO in complex with vismodegib (PBD ID: 5L7I; lime green), DCRD–SMO in complex with LY2940680 (PBD ID: 4JKV;
orange), DCRD–SMO in complex with Anta XV (PDB ID: 4QIM; marine), DCRD–SMO in complex with SAG 1.5 (PDB ID: 4QIN; yellow), DCRD–SMO in
complex with SANT1 (PDB ID: 4N4W; magenta) and DCRD–SMO in complex with Cyclopamine (PDB ID: 4O9R; cyan) are superimposed and shown as
cartoons. (e) Superimposed structures of SMO CRDs. CRD from multi-domain SMO structure solved at XFEL (light blue), CRD from multi-domain SMO
structure in complex with cholesterol (PBD ID: 5L7D; pink), CRD from xSMO in the apo state (PBD ID: 5KZZ; cyan), CRD from xSMO in complex with
20(S)-OHC (PBD ID: 5KZV; deep blue) and CRD from xSMO in complex with cyclopamine (PBD ID: 5KZY; green) are shown in cylindrical helices.
Key residues, cholesterol, 20(S)-OHC and cyclopamine are shown in sticks.
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signalling, suggesting a modulatory role of this region to SMO
activation by oxysterols (Supplementary Fig. 8). This result is also
consistent with a previous report that 20(S)-OHC activates
SMO in a distinct way compared to endogenous signalling12.
Meanwhile, our HDX analysis indicated the existence of an
intrinsic flexibility at the cytoplasmic side of the TMD, which
could allow for further conformational changes on signal
transduction. We suggest that the outward tilt of upper helix
VI and ECL3, and the displacement of the HD are likely to be
responsible for triggering a conformational change in the receptor
and activating it. However, this hypothesis still requires further
verification.
It has been shown that the CRD exerts allosteric modulation of
the TMD11, and vice-versa, affecting ligand recognition and
receptor activation. Similarly, the glucagon receptor (GCGR),
a Class B GPCR, also employs a multi-domain architecture for
ligand recognition and activation. GCGR has unambiguously
distinct states defined as an ‘open/closed’ switch, as revealed by
computer modelling of the full length receptor24. Extensive
biophysical and computational analysis of GCGR have proposed
an activation mechanism for GCGR on glucagon binding. In the
absence of the endogenous peptide ligand glucagon, GCGR
adopts a dynamic conformation, where the ECD, an equivalent
counterpart of the CRD in GCGR, undergoes a large-scale
swinging motion between an open state, in which the ECD points
into the extracellular space away from the membrane, and a
closed state, in which the ECD lays on top of the ECLs of the
TMD. When glucagon binds to GCGR, it stabilizes the receptor in
the ‘open’ conformational state, where the ECD is oriented almost
perpendicular to the membrane surface allowing the N-terminus
of glucagon to enter in the TMD binding site and activate the
receptor. In SMO, by contrast, the range of CRD motion appears
to be limited in the consideration of the structure analysis and
HDX results. Agonist binding to the CRD first triggers a small tilt
of the CRD, which pushes helix VI and ECL3 outward. Such a
combined tilt possibly leads to an amplified conformational
change along with a downward movement of the HD, thereby
transmitting the signal to the TMD and activating the receptor.
However, no such TMD conformational changes have yet been
observed in any SMO structure, possibly due to the ICL3 fusions
employed or crystal packing. Thus, capturing a fully active SMO
conformation may require the presence of an intracellular
binding partner to which signal is transmitted.
SMO is a validated target for anti-cancer drugs. There are
two FDA approved drugs acting through regulation of SMO
mediated signalling pathway: vismodegib (GDC-0449) (ref. 17)
and sonidegib (LDE-225) (ref. 25) for the treatment of basal cell
carcinoma. Both are SMO antagonists bound to TMD. Long-term
administration of these drugs, however, can lead to the
development of resistance26,27. In this work, we applied a
successful strategy towards the design of a new tool compound
for the crystallographic study of a challenging GPCR. As a drug
candidate in phase 2 clinical trials with Eli Lilly, LY2940680 is
being employed to treat small-cell lung cancer28, and was the first
ligand used successfully in a SMO structural study. Nevertheless,
for crystallization of the multi-domain SMO, LY2940680 had to
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be modified to stabilize the complex CRD–TMD interaction.
Four-fluorine was originally introduced in the benzoyl group of
LY2940680 to potentially block the rapid metabolism that is a
usual strategy to optimize ADME property in drug discovery.
This substitution was however detrimental to the stability and
crystallization of the receptor. Although medicinal chemists
generally try to avoid the nitro group, especially attached to an
aromatic ring, which is known to be easily reduced as well as to
carry toxic effects, the design of the TC114 tool compound by the
replacement of the 4-fluorine with the 4-nitro group in
LY2940680 has been one of the key factors that led to the
multi-domain SMO structure determination. We therefore are
optimistic about the possibility of extending this design strategy
to other in-progress receptors. The multi-domain SMO structure
may inspire the design of a new type of small molecule that links
the CRD and TMD, or interacts with the HD to regulate domain-
domain communications that can potentially exert amplified
efficacy and overcome drug resistance. Alternatively, drugs
designed for CRD binding grooves could also be explored to
circumvent the resistance resulting from mutations in the TMD.
The structure offers insights into the conformational modularity
of SMO multi-domains and provides new opportunities for the
design of ligands to battle SMO-related diseases.
Methods
Synthesis of TC114. A solution of 4-nitro-2-(trifluoromethyl)benzoic acid
(80mg, 0.34mmol), secondary amine N-methyl-1-(4-(1-methyl-1H-pyrazol-5-yl)
phthalazin-1-yl)piperidin-4-amine (100mg, 0.31mmol) and N,N-diisopropylethy-
lamine (DIPEA, 60mg, 80 ml, 0.46mmol) in 3ml of CH2Cl2 were treated with
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate (HATU, 153mg, 0.40mmol). The reaction mixture was
stirred at room temperature for 1 h before being quenched by the addition of brine.
The reaction mixture was extracted three times with CH2Cl2. The combined
organic layer was washed with saturated NaHCO3 solution and brine sequentially,
then dried over Na2SO4. After filtration, the solution was concentrated in vacuum
and the crude product was purified by flash column chromatography on silica gel
to yield TC114, as a colourless solid (82mg, 49%). Nuclear magnetic resonance
showed a mixture of rotamers.
Table 1 | Crystallographic data collection and refinement statistics.
Data collection and refinement statistics
Data set flSMO_XFEL flSMO_Synchrotron
Temperature (C) 20 (Room temperature)  196
Space group P21 P21
Cell dimensions
a,b,c (Å) 40.6 349.5 61.8 40.1 356.4 59.1
b (deg) 101.1 102.8
Number of reflections measured 13,583,207 109,498
Number of unique reflections 37,101 29,571
Resolution (Å) 24.90–2.90 (3.00–2.90) 48.38–3.00 (3.16–3.00)
Rmerge or Rsplit 13.3 (280) 11.7 (39.3)
Mean I/s (I) 5.4 (0.4) 7.5 (1.9)
Completeness (%) 100 (100) 91.9 (81.3)
Redundancy 366 (64.5) 3.7 (2.3)
CC* 0.9986 (0.584) 0.998 (0.875)
Refinement
Resolution (Å) 24.90–2.90 48.38–3.00
Number of reflections (test set) 37,045 (1,810) 29,552 (1,502)
Rwork/Rfree 0.218/0.239 0.203/0.240
Number of atoms
A B A B
SMO 3,770 3,778 3,878 3,871
Flavodoxin 1,099 1,100 1,103 1,097
TC114 39 39 39 39
Other 45 31 31 43
Average B Factor (Å2)
Wilson/Overall 82.2/117.3 72.6/82.7
A B A B
SMO 127.1 121.8 93.2 87.3
Flavodoxin 97.8 90.8 59.6 55.0
TC114 93.6 105.5 82.5 74.4
Other 106.2 63.3 52.8 55.1
r.m.s.d.’s
Bond lengths (Å) 0.009 0.009
Bond angles (deg) 1.03 0.93
Ramachandran plot statistics (%)*
Favored regions 95.2 94.1
Allowed regions 4.8 5.9
Disallowed regions 0 0
Data for high resolution shells is shown in parenthesis where applicable.
*As defined in MolProbity52.
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Engineered SMO-FLA fusion construct for structural studies. The wild-type
(WT) human SMO gene was synthesized by Genescript and then cloned into a
modified pTT5 vector containing an expression cassette with an HA signal
sequence followed by a FLAG tag, a 10His tag, and a tobacco etch virus (TEV)
protease recognition site at the N terminus before the receptor sequence and
another 10His tag at the C-terminus. A small protein Flavodoxin (FLA, MW
16KD)16 was fused to ICL3 between P434 and S443, using overlapping PCR. The N
terminus 1–52 and C terminus 559–787 were truncated. A single-mutation E194M
in the HD was introduced for the construct, crystals of which were used for data
collection at XFEL. The construct used for synchrotron structure determination
does not contain the point mutation and was slightly modified by further
truncating the N terminus by five residues. All primer sequences used in this study
are shown in Supplementary Table 1.
Expression and purification of SMO-FLA fusion protein. The engineered SMO
construct was expressed in HEK293F cells (Invitrogen) in the presence of 5 mM
vismodegib. HEK293F cells at a cell density of 1.0 1.3 106 cellsml 1 were
transiently transfected with PEI:DNA at a ratio of 2:1, and cultured at 37 C. Cells
were collected 48 h, after transfection and stored at  80 C until use. Cell pellets
were re-suspended in a hypotonic buffer (10mM HEPES, pH 7.5, 10mM MgCl2,
20mM KCl and EDTA-free protease inhibitor cocktail tablets (Roche)). Further
washing of the raw membranes was performed by repeated centrifugation (three
times) in a high salt buffer (10mM HEPES, pH 7.5, 10mM MgCl2, 20mM KCl,
1.0M NaCl and EDTA-free protease inhibitor cocktail tablets). The washed
membranes were re-suspended in a buffer containing 30 mM TC114, 2mgml 1
iodoacetamide (Sigma) and EDTA-free protease inhibitor cocktail tablets, and
incubated on a rocker at 4 C for 1 h. The membranes were then solubilized in a
buffer containing 50mM HEPES, pH 7.5, 200mM NaCl, 1% (w/v) n-dodecyl-b-D-
maltopyranoside (DDM, Anatrace) and 0.2% (w/v) cholesteryl hemisuccinate
(CHS, Sigma), for 2.5 h at 4 C. After high-speed centrifugation, the supernatant
was incubated with TALON IMAC resin (Clontech) overnight at 4 C supple-
mented with 20mM imidazole and 1.0 M NaCl. After binding, the resin was
washed with 10-column volumes of wash I buffer (50mM HEPES pH 7.5, 800mM
NaCl, 10% glycerol, 0.5% (w/v) Lauryl Maltose Neopentyl Glycol (LMNG,
Anatrace)/0.1% CHS, 20mM Imidazole, 10mM MgCl2, 6mM ATP and 30mM
TC114). The beads with 2ml wash I buffer were transferred to a 5ml tube and
incubated on a rocker at 4 C for 2 h for complete detergent exchange, followed by
washing with six-column volumes of wash II buffer (25mM HEPES pH 7.5,
500mM NaCl, 10% glycerol, 0.03% LMNG/0.006% CHS, 40mM Imidazole
and 50mM TC114). The protein was then eluted by three-column volumes of
elution buffer (25mM HEPES pH 7.5, 300mM NaCl, 10% glycerol, 0.01%
LMNG/0.002% CHS, 220mM Imidazole and 100mM TC114). The protein was
then treated overnight with TEV protease and Endo H (NEB) to cleave the
N-terminal His tag, FLAG tag and additional glycans. The protein was then
concentrated to 40-50mgml 1 with a 100 kDa cutoff Vivaspin concentrator.
Protein monodispersity was tested by analytical size-exclusion chromatography
(aSEC). Typically, the aSEC profile showed a monodisperse peak.
Crystallization in LCP for synchrotron data collection. Protein samples of the
SMO receptor in a complex with TC114 were reconstituted into lipidic cubic phase
(LCP) by mixing with molten lipid (10% (w/w) cholesterol, 90% (w/w) monoolein)
at a ratio of 2/3 (v/v) protein solution/lipid using a mechanical syringe mixer29.
LCP crystallization trials were performed using an NT8-LCP crystallization robot
(Formulatrix)30 in 96-well glass sandwich plates (Nova). After setup, plates were
incubated and imaged at 20 C using an automated incubator/imager (RockImager
1000, Formulatrix). Initial crystal hits were found in a precipitant condition
containing 100mM Sodium citrate tribasic dihydrate, pH 5.0, 30% (v/v) PEG400,
100mM Ammonium nitrate. After optimization, crystals grew in 100mM Sodium
citrate tribasic dihydrate pH 5.0, 36% (v/v) PEG400, 50–200mM Ammonium
nitrate to the average size of 47 23 8 mm3 within 7 d. The SMO crystals were
collected directly from LCP using 30 mm micromounts (MiTeGen) and flash frozen
in liquid nitrogen for data collection.
Synchrotron data collection and structure determination. X-ray diffraction data
were collected at the SPring-8 beam line 41XU, Hyogo, Japan, using a Pilatus3 6M
detector (X-ray wavelength 10,000Å). The crystals were exposed with a 10 mm
mini-beam for 0.2 s and 0.2 oscillation per frame. XDS31 was used for integrating,
scaling and merging data from 12 best-diffracting crystals of the SMO–TC114
complex. Initial phase information of the SMO-TC114 complex was obtained by
molecular replacement (MR) with Phaser32 using the TMD of human–SMO
(PDB ID: 4QIM)8, CRD of zebrafish SMO (PDB ID: 4C79)33, and a Flavodoxin
structure (PDB ID: 1I1O)34 as search models. The correct MR solution contained
two SMO molecules packed tail-to-tail in one asymmetric unit of the P21 lattice.
Refinement was performed with REFMAC5 (ref. 35) and autoBUSTER36 followed
by manual examination and rebuilding of the refined coordinates in the program
COOT37 using both |2Fo|–|Fc| and |Fo|–|Fc| maps. NCS and TLS refinement with
two TLS groups (SMO and Flavodoxin domains) were incorporated in the
refinement. The final model of the synchrotron SMO-TC114 complex contains
498 residues of SMO (residues 58–433 and 444–565) and the 147 residues of
Flavodoxin in molecule A, and 494 residues of SMO (residues 58–433 and
444–561) and 147 residues of Flavodoxin in molecule B. Data collection and
refinement statistics of the synchrotron structure are summarized in Table 1.
Crystallization in LCP for XFEL data collection. Crystals for LCP–XFEL were
obtained in Hamilton gas-tight syringes as previously described38 by injecting
B5 ml of protein-laden LCP as a continuous column ofB400 mm in diameter into
a 100 ml syringe filled with 60ml of precipitant solution containing 100mM Sodium
citrate tribasic dihydrate, pH 5.0, 36% (v/v) PEG400, 150mM Ammonium
Chloride and incubated for at least 24 h at 20 C. After crystals (average size
5 5 2 mm3) formed, samples from 2 to 3 syringes were consolidated together
and the excess of precipitant solution was removed. The residual precipitant
solution was absorbed by addition of a few microliter of molten 7.9 MAG lipid39.
The resulting crystal-laden LCP sample was inspected under a visual microscope
and loaded in an LCP injector9 for LCP-SFX data collection.
XFEL data collection and structure determination. The experiment was carried
out at the Coherent X-ray Imaging end station40 of the LCLS, using 9.5 keV (1.3 Å)
X-ray pulses with a pulse duration of 45 fs and a repetition rate of 120Hz.
SMO–TC114 crystals were delivered to the intersection with a 1.5 mm XFEL beam
inside a vacuum chamber within a 50 mm diameter stream of LCP at a flow rate of
B200 nlmin 1 generated by an LCP injector. Serial femtosecond crystallography
(SFX) data were collected by a CSPAD detector positioned at a distance 106mm
from the sample. The beam was attenuated to 7.5–11% (B1011 photons per pulse)
of the full intensity to avoid detector saturation. A total of 2,102,907 diffraction
patterns were collected, of which 320,121 were identified as potential single crystal
diffraction hits with 415 potential Bragg peaks by the software Cheetah41,
corresponding to an average hit rate of 15.2%. Auto indexing and structure factor
integration of the crystal hits was performed using CrystFEL (version 0.6.2)42 with
a ‘pushres 1.2’ option, resulting in 65,560 indexed images with a monoclinic lattice
(20.5% indexing success rate). Initial phase information for the XFEL structure of
the SMO–TC114 complex was obtained by molecular replacement (MR) with
Phaser32 using our synchrotron structure with CRD, TMD and Flavodoxin
domains as independent search models. An MR trial with the multi-domain SMO
synchrotron structure as a single search model was not successful. The correct MR
solution contained two SMO–TC114 molecules packed tail-to-tail in one
asymmetric unit of the P21 lattice, similar to the synchrotron structure. Refinement
was performed with REFMAC5 (ref. 35) and autoBUSTER36 followed by manual
examination and rebuilding of the refined coordinates in the program COOT37
using both |2Fo| |Fc| and |Fo| |Fc| maps. NCS restraints were used during the
refinement. Addition of TLS groups decreased the quality of the R/Rfree statistics
and, therefore, TLS was not used in the refinement. The final model of the
SMO–TC114 complex contains 485 residues of SMO (residues 59–433 and
444–553) and the 147 residues of Flavodoxin (residues 1002–1148) in molecule A,
487 residues of SMO (residues 59–433, 444–498 and 505–561) including uncleaved
C-term Histag (559–561) and the 147 residues of Flavodoxin (residues 1002–1148)
in molecule B. The remaining N-terminal residues (residues 53–58 in molecules
A and B), part of ECL3 (residues 499–504 in molecule B) and C-terminal residues
(554–558 in molecule A) are likely disordered and not visible in the electron
density maps, and therefore were not modelled. Data collection and refinement
statistics of the XFEL structure are summarized in Table 1.
Hydrogen-Deuterium exchange mass spectrometry analysis. Hydrogen-
Deuterium exchange mass spectrometry (HDX-MS) employed a SMO construct
similar to the crystallization construct (SMO-FLA), except that the fusion partner
was replaced by a smaller protein Rubredoxin (RUB, MW 6KD) inserted into ICL3
between P434 and S443 (SMO-RUB), and the experiment was carried out at 4 C as
follows. Briefly, 25mM of purified protein as apo (no ligand) was mixed with
250 mM of TC114, or with 250mM of OHC, or with 250mM of NHC and incubated
in a D2O buffer for a range of exchange times from 10 s to 1 h before quenching the
deuterium exchange reaction with an acidic quench solution (pH 2.4). All mixing
and digestions were carried out on a LEAP Technologies Twin HTS PAL liquid-
handling robot housed inside a temperature-controlled cabinet24,43. Digestion was
performed in line with chromatography using an immobilized pepsin column.
Mass spectra were acquired on a Q Exactive hybrid quadrupole-Orbitrap mass
spectrometer (Thermo Scientific) and per cent deuterium exchange values for
peptide isotopic envelopes at each time point were calculated and processed using
the HDX Workbench software44. The data are presented as an average±s.d. of
three independent replicates. Data were fitted to a simple nonlinear regression
(least squares) best fit model (X is log and Y is linear) using GraphPad Prism.
MD simulation. Protein preparation and system building. The crystal structure of
SMO receptor with cholesterol was obtained from the PDB database (PDB code:
5L7D20). The chain A of the structure was selected to build the model. Prime45 in
Schro¨dinger Release 2015-3 was used and ICL3 was built by a homology model
using another crystal structure of Smo (PDB code: 4JKV (ref. 3)), and ICL2 loop
was predicted by Prime. The model was refined by Prepwizard46 in pH at 7.0, and
the C- or N-terminal was capped by ACT and NME.
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The membrane around the transmembrane domain of SMO receptor was
built by 135 POPC molecules and 48 cholesterols using CHARMM-GUI web
server47. The final periodic boundary system box is 84.75 84.75 139.85 Å, and
20881 TIP3P waters and 62 Naþ and 68 Cl ions (0.15mol l 1 NaCl) were used
to solvate and neutralize the box. The system had a total of 93,475 atoms per
periodic cell.
Molecular dynamic simulation and data analysis. The Amber99sb-ILDN48 force
filed was applied on SMO receptor, TIP3P water and ions, and the Slipids49 force
field was applied for cholesterol and POPC. Gromacs 5.1.2 (ref. 50) was used for
the simulation, and the relaxation protocol was obtained from CHARMM-GUI
and described in their paper and web server. First, the system is minimized in
10,000 steps by steepest-descent procedure, and equilibrated at constant
temperature (303.15 K) and constant pressure (1.0 bar) in 50 ps NVT condition and
125 ps NPT condition with strong restraints on protein and lipids and a
nonbonded cutoff switching ranges of 10–12Å. Subsequently, 2 ns NPT
equilibration in the same condition with weak restraints of protein and lipids was
performed to get the equilibrated phase. Finally, two identical 1,000 ns product MD
simulations were performed on the SMO receptor and cholesterol as ligand in
lipids and water system.
The result of product MD simulation was analysed by Gromacs 5.1.2. The angle
defined by three atoms (the C-alpha of P69, V210 and W535) was selected to
describe the tilt of SMO CRD relative to SMO TMD.
Hedgehog signalling assay. Light II cells (ATCC; Rockville, MD) with stable
ectopic expression of 8Gli binding site-firefly luciferase and constitutive Renilla
luciferase reporter constructs were seeded into 96-well plates. After transfection
with either Smoothened wild type or distinct Smoothened mutant plasmids as
indicated, the cells were subjected to various treatments as indicated for 36 h.
Luciferase activity in light II cells was measured using the Dual-Luciferase Assay
System kit from Promega (according to the manufacturer’s instructions in a
luminometer (Molecular Devices; Sunnyvale, CA)) (Madison, WI), and was
normalized to Renilla values. Data were plotted, and IC50 values were determined
using GraphPad Prism. Each data point represents the mean±s.d. repeated in
triplicates.
Western blot analysis. Cells after various transfections as indicated were collected
and subjected to lysis buffer (50mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, 1mM
sodium vanadate, 1mM PMSF, 1mM DTT, 10mgml 1 of leupeptin and
aprotinin), followed by immunoblot analysis. Primary antibodies against SMO
and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used for
immunoblot analysis according to the routine procedure51. The antibodies against
SMO and GAPDH are diluted at 1:200 and 1:5,000, respectively, according to
manufacturer’s instruction.
Data availability. Coordinates and structure factors have been deposited in
the Protein Data Bank for SMO-TC114 solved at XFEL (PDB: 5V56) and at
synchrotron (PDB: 5V57). The PDB accession codes 4JKV, 5L7D, 5L7I, 4QIM,
4QIN, 4N4W, 4O9R, 5KZZ, 5KZV, 5KZY, 5CL1, 4F0A were used in this study.
The UniProt accession codes Q99835 for human SMO was used in this study.
All other data are available from the corresponding authors on reasonable request.
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